Aug 27, 2008
Study outcome won't sway company on eye drug
What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other ...
Read full story from Kpic.com
Comments
Showing posts
1 - 1 of 1
|
what do you think this is new! Wake up! It's all about the money! Follow the money and you will always get your answer. For the people by the people! Right!
|
Judge it!
Showing posts
1 - 1 of 1
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Merck to fund Vioxx settlement in August | 1 hr | DJ -SMD | 1319 |
| MPI Research cutting jobs in Mattawan | 2 hr | Harold | 5 |
| Claims administrator: Interim payments in $4.85... | 3 hr | heraldo | 983 |
| Buffalo - The Next Cleveland? | 4 hr | Wow | 14 |
| Cymbalta leads the way for Lilly (from Feb '07) | 4 hr | edd | 232 |
| Vioxx claimants rush to join $4.85B settlement ... (from Jan '08) | 4 hr | IronLady | 647 |
| Teva Announces Launch of Generic Zoloft (from Nov '06) | 7 hr | KGH Monroe NC | 1113 |
Related Topix Forums:
Medicine,
Family,
Law,
Healthcare Industry,
Healthcare Law,
Startups,
Elderly,
Genentech,
Genentech
Taurus
Most Popular